Skip to main content

Quality of life following adherence therapy for people disabled by schizophrenia and their carers (QUATRO)

Objective

Ant psychotic medication has well-established effectiveness in the treatment of people with schizophrenia. However, adherence to medication is a very common problem, and non-adherence increases the risk of relapse disability, and poor quality of life. The "Quality of Life following Adherence Therapy for People Disabled by Schizophrenia and their Carers" study is a randomised controlled trial and will investigate the effectiveness and cost effectiveness of adherence therapy designed to improve quality of life among schizophrenic patients and their carers. The study is expected to contribute to evidence-based practice in the care for people who suffer from schizophrenia, and their carers, across Europe.

Funding Scheme

CSC - Cost-sharing contracts
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

KING'S COLLEGE LONDON
Address
De Crespigny Park, Denmark Hill
SE5 8AF London
United Kingdom

Participants (3)

ACADEMISCH ZIEKENHUIS BIJ DE UNIVERSITEIT VAN AMSTERDAM
Netherlands
Address

1100 DD Amsterdam
UNIVERSITA DEGLI STUDI DI VERONA
Italy
Address
Via Delle Menegone 10
37134 Verona
UNIVERSITAET LEIPZIG
Germany
Address
Liebigstrasse 22 B
04103 Leipzig